Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2

1. Verma, S. K. et al. New-age vaccine adjuvants, their development, and future perspective. Front. Immunol. 14, 1043109. https://doi.org/10.3389/fimmu.2023.1043109 (2023).

   Google Scholar 

2. Pulendran, B., Arunachalam, P. S. & O’Hagan, D. T. Emerging concepts in the science of vaccine adjuvants., Nat. Rev. Drug Discov., 20 (6), 454–475 (2021). https://doi.org/10.1038/s41573-021-00163-y

3. Audran, R. et al. Mar., Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro., Vaccine, 21(11–12), 1250–1255 (2003). https://doi.org/10.1016/s0264-410x(02)00521-2

4. Langer, R., Cleland, J. L. & Hanes, J. New advances in microsphere-based single-dose vaccines., Adv. Drug Deliv. Rev., 28(1), 97–119 (1997). https://doi.org/10.1016/s0169-409x(97)00053-7

5. Jiménez-Periáñez, A. et al. Mesoporous silicon microparticles enhance MHC class i cross-antigen presentation by human dendritic cells. Clin. Dev. Immunol. 2013 https://doi.org/10.1155/2013/362163 (2013).

6. Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J. & Peiffer-Smadja, N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review., Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., 28(2), 202–221 (2022). https://doi.org/10.1016/j.cmi.2021.10.005

7. Doria-Rose, N. et al. Jun., Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19., N. Engl. J. Med., 384(23), 2259–2261 (2021). (United States) https://doi.org/10.1056/NEJMc2103916

8. Barouch, D. H. et al. Sep., Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination., N. Engl. J. Med., 385(10), 951–953 (2021). (United States) https://doi.org/10.1056/NEJMc2108829

9. Yang, L. T. et al. Aug., Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients., Clin. Immunol., 120(2), 171–178 (2006). https://doi.org/10.1016/j.clim.2006.05.002

10. Enjuanes, L. et al. Molecular basis of coronavirus virulence and vaccine development. Adv. Virus Res. 96, 245–286. https://doi.org/10.1016/bs.aivir.2016.08.003 (2016).

    Google Scholar 

11. Channappanavar, R., Zhao, J. & Perlman, S. T cell-mediated immune response to respiratory coronaviruses. Immunol. Res. 59, 1–3. https://doi.org/10.1007/s12026-014-8534-z (2014).

    Google Scholar 

12. López-Gomez, A., Real-Arévalo, I., Martín-Palma, R., Martínez-Naves, E. & Del Moral, M. G. Manufacture of mesoporous silicon microparticles (MSMPs) as adjuvants for vaccine delivery. Methods Mol. Biol. 2673, 123–130. https://doi.org/10.1007/978-1-0716-3239-0_8 (2023).

    Google Scholar 

13. Alcolea, P. J. et al. Non-replicative antibiotic resistance-free DNA vaccine encoding S and N proteins induces full protection in mice against SARS-CoV-2. Front. Immunol. 13, 1023255. https://doi.org/10.3389/fimmu.2022.1023255 (2022).

    Google Scholar 

14. Navarro-Tovar, G., Rocha-García, D., Wong-Arce, A., Palestino, G. & Rosales-Mendoza, S. Mesoporous silicon particles favor the induction of long-lived humoral responses in mice to a peptide-based vaccine. Mater. (Basel). 11 (7). https://doi.org/10.3390/ma11071083 (2018).

15. Castillo, R. R. et al. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update., Expert Opin. Drug Deliv., 16(4), 415–439 (2019). https://doi.org/10.1080/17425247.2019.1598375

16. Abbaraju, P. L. et al. Asymmetric Silica Nanoparticles with Tunable Head-Tail Structures Enhance Hemocompatibility and Maturation of Immune Cells. J. Am. Chem. Soc. 139, 6321–6328. https://doi.org/10.1021/jacs.6b12622 (2017).

    Google Scholar 

17. Yan, J. et al. Porous silicon and silica carriers for delivery of peptide therapeutics., Drug Deliv. Transl. Res., 14(12), 3549–3567 (2024). https://doi.org/10.1007/s13346-024-01609-7

18. Abbaraju, P. L. et al. Asymmetric mesoporous silica nanoparticles as potent and safe immunoadjuvants provoke high immune responses., Chem. Commun. (Camb)., 54(16), 2020–2023 (2018). https://doi.org/10.1039/c8cc00327k

19. Janeway, C. A. J. Approaching the asymptote? Evolution and revolution in immunology., Cold Spring Harb. Symp. Quant. Biol., 54(1), 1–13 (1989). https://doi.org/10.1101/sqb.1989.054.01.003

20. Liu, Z. et al. Size effect of mesoporous silica nanoparticles on regulating the immune effect of oral influenza split vaccine. Colloids Surf. B Biointerfaces 238, 113920. https://doi.org/10.1016/j.colsurfb.2024.113920 (2024).

    Google Scholar 

21. García-Pérez, J. et al. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. EClinicalMedicine 50, 101529. https://doi.org/10.1016/j.eclinm.2022.101529 (2022).

    Google Scholar 

22. Lin, Q., Zhu, L., Ni, Z., Meng, H. & You, L. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection., Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 53 (5), 821–822 (2020). (England) https://doi.org/10.1016/j.jmii.2020.03.015

23. Flaxman, A. et al. Sep., Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)., Lancet (London, England), 398 (10304), 981–990 (2021). https://doi.org/10.1016/S0140-6736(21)01699-8

24. Nazeri, S., Zakeri, S., Mehrizi, A. A., Sardari, S. & Djadid, N. D. Measuring of IgG2c isotype instead of IgG2a in immunized C57BL/6 mice with plasmodium Vivax TRAP as a subunit vaccine candidate in order to correct interpretation of Th1 versus Th2 immune response. Exp. Parasitol. 216 https://doi.org/10.1016/J.EXPPARA.2020.107944 (Sep. 2020).

25. Adam, A. et al. Nov., A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine., Transl. Res., 249, 13–27 (2022). https://doi.org/10.1016/j.trsl.2022.06.004

26. Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588(7839), 682. https://doi.org/10.1038/S41586-020-2852-1 (2020).

    Google Scholar 

27. Li, H. et al. The abundant distribution and duplication of SARS-CoV-2 in the cerebrum and lungs promote a high mortality rate in Transgenic hACE2-C57 mice. Int. J. Mol. Sci. 25 (2). https://doi.org/10.3390/ijms25020997 (2024).

28. Starr, T. N. et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. Cell 182(5), 1295–1310. https://doi.org/10.1016/J.CELL.2020.08.012 (2020) (.e20).

    Google Scholar 

29. Liu, H. et al. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2. Cell. Res. 31(6), 720–722. https://doi.org/10.1038/S41422-021-00496-8 (2021).

    Google Scholar 

30. García-Arriaza, J. et al. Mar., COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice, J. Virol., 95(7), (2021). https://doi.org/10.1128/JVI.02260-20

31. He, P., Zou, Y. & Hu, Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum. Vaccin Immunother. 11 (2), 477. https://doi.org/10.1080/21645515.2014.1004026 (2015).

    Google Scholar 

32. Hudu, S. A., Shinkafi, S. H. & Umar, S. An overview of Recombinant vaccine technology, adjuvants and vaccine delivery methods. Int. J. Pharm. Pharm. Sci. 8 (11), 19–24. https://doi.org/10.22159/ijpps.2016v8i11.14311 (2016).

    Google Scholar 

Download references

Author notes

1. Eduardo Martínez-Naves & Manuel Gómez del Moral

   Present address: Instituto de Investigación Sanitaria Hospital 12 Octubre (imas12), Madrid, 28041, Spain

2. These authors contributed equally to this work: Eduardo Martínez-Naves and Manuel Gómez del Moral.

Authors and Affiliations

1. Department of Cellular Biology and Histology, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain

   Ana López-Gómez, Elsa Mayol-Hornero, Jana Ausio Cendra & Manuel Gómez del Moral

2. Department of Immunology, Ophthalmology and ORL, School of Medicine, Universidad Complutense of Madrid (UCM), Madrid, 28040, Spain

   Ana López-Gómez, Irene Real-Arévalo, Elsa Mayol-Hornero, Benigno Rivas-Pardo, Beatriz Amorós-Pérez, Beatriz Martín-Adrados, Ignacio Juárez & Eduardo Martínez-Naves

3. Inmunotek S.L., Alcalá de Henares, 28805, Spain

   Irene Real-Arévalo & Beatriz Amorós-Pérez

4. Department of Biochemistry and Molecular Biology, School of Chemistry, Universidad Complutense of Madrid, Madrid, 28040, Spain

   Diego Laxalde-Fernández & Álvaro Martínez-Del-Pozo

5. Department of applied physics, Universidad Autónoma de Madrid, Madrid, España

   Raúl J. Martín-Palma

6. Centro de Investigación en Sanidad Animal, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria, Consejo Superior de Investigaciones Científicas (CISA-INIA‐CSIC), Valdeolmos, Madrid, Spain

   Pablo Nogales-Altozano & Noemí Sevilla

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by A.L-G., I.R-A., E.M-H., J.A.C., D.L-F., P. N-A., B R-P., B. A-P., B. M-A. and I. J. The first draft of the manuscript was written by M. G. M., E.M.N., and A. L-G. N.S., A. M-del-P. and R. J. M-P. commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Eduardo Martínez-Naves or Manuel Gómez del Moral.

Competing interests

The authors declare no competing interests.

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Universidad Complutense of Madrid and Comunidad of Madrid (Dec 14/2022/PROEX 272.5/22).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions